Company intelligence / Profile preview
Symberix
Durham or Chapel Hill area [company spun out from UNC-Chapel Hill but based in Durham per source], North Carolina, United Statessymberix.net ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Symberix is a preclinical-stage biotech company developing first-in-class small-molecule drugs that selectively inhibit harmful activities of gut bacteria without killing beneficial microbes. Their lead candidate SBX‑101 targets bacterial β-glucuronidase to improve outcomes for IBD patients using NSAIDs. A second program, SBX‑3, targets both bacterial GUS and an undisclosed human immune/inflammatory pathway. No clinical results have been reported as all programs are preclinical.[1][2][5]
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecules (specifically, small-molecule symbiotic drugs and bacterial β-glucuronidase inhibitors)[1][2]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
University of North Carolina at Chapel Hill/UNC Kickstart Ventures collaboration/support[1][5]
Beyond the preview
Go deeper on Symberix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Symberix.